General comments This is an interesting study that addresses an important issue of real life clinical practice in management of ARS, a very common disease, among primary care physician (PCPs) and Otorhinolaryngologists (ORLs) in Spain. It has been shown internationally as an important medical issue on standardization of diagnosis and management in patients with ARS, in particularly the abuse of antibiotics in treatment of uncomplicated ARS. In the past 10-20 years, there are a number of international guidelines/consensus reports which have been recommended and disseminated by various medical organizations. Therefore, it is time to investigate the outcomes and compliance of these documents in real practice worldwide. Specific comments 1.
It is know that there is so far no validated criterion to define bacterial ARS, especially in epidemiology or questionnaire survey study. Are there any objective measures which can be suggested by the authors? 2.
Although it appears to be similar in this study, is there a typical symptom (s) or question (s) that is sensitive enough to differentiate between patients with ARS and postviral ARS? 3.
Based on your exclusion criteria, did you exclude more patients with postviral ARS than ARS? 4.
Page 8, line, 34, home environment, what does the "Airy" meaning to? Here you have mentioned "well-heated", but in the Results, you have mentioned only "air-conditioned environment" (Page 12, line 50). 5.
In Fig 1, the number of percentage is confusion and need to be revised. 6.
In Fig 1, the severity of disease is based on "VAS of pain" that is NOT same as it is mentioned in Methodology.
The authors are to be commended on the difficult topic selected and on the size of the trial population. I appreciate the "real life" format. While I agree that the observational trial format limits the conclusions it can be drawn, it nevertheless represents a picture of actual clinical practice which is difficult to get from highly restrictive drug registration trials.
In addition, this addresses a little studied population -the sub-acute population (greater than ten days and less than twelve weeks of symptoms) -of which the natural evolution has, to my knowledge, never been described.
However, I would argue that the article attempts to somewhat over reach beyond its stated objectives and that this hampers it somewhat. With revision, the points that are demonstrated about the study are of importance and would make the article publicationworthy in this area where evidence is sorely lacking.
However, a limited number of issues decrease the potential value of the manuscript. It could probably be improved by addressing these, and would give this otherwise very interesting paper the diffusion it deserves.
Comments are as follows: I) 'Viral' sinusitis for acute sinusitis This presupposes that all acute sinusitis is viral, but this is not correct. While sinusitis episodes are frequently triggered by a respiratory virus, puncture studies suggest that significant levels of pathogens can be identified in 30-35% of appropriately diagnosed patients. These cases can and do resolve without antibiotics, hence presence of bacteria in acute sinusitis does not necessarily mean the patient requires an antibiotic treatment. However, I believe it is incorrect to term this 'viral' as opposed to the catch all 'sinusitis' term which describes simply inflammation of the sinus. II) Inclusion of patients from GPs. This is simple recollection of previous treatments and not prospectively collected data like that obtained from the ENTs. Given this important bias, the two are simply not comparable. III) Unbalanced discussion of the usefulness of corticosteroids and management of acute sinusitis A more complete discussion of corticosteroids for ARS would include the other published (and unpublished) trials showing weaker or no effect. This topic remains controversial. IV) Abuse versus overuse. The authors use the term 'according to guideline recommendations' (best practices) which I prefer to 'abuse'. It is clear that physicians do not always adhere to guidelines-however, we may not have understood how to best serve their needs either so the dialogue needs to be ongoing. V) Lack of clinical pearls for the reader on management of sub-acute sinusitis. Pearls on understanding and managing this oft-ignored entity are scattered throughout the text. A summary statement could help group these in a quick vignette e.g., " Management is similar as for ABRS and disease can be expected to resolve even when moderate or severe symptoms are present. A corticosteroid appeared to help benefit resolution" or along those lines.
VERSION 1 -AUTHOR RESPONSE
REVIEWER 1 COMMENT 1. It is know that there is so far no validated criterion to define bacterial ARS, especially in epidemiology or questionnaire survey study. Are there any objective measures which can be suggested by the authors? ANSWER 1. We agree with the reviewer to validate diagnostic criteria for bacterial ARS is a very important unmet need. However, this was considered out of the objectives of the PROSINUS study due to the lack of validated tools. In fact, "patients with clinical suspicion of bacterial ARS" was considered an exclusion criteria (page 9, lines 2-4) in our study. To address this point, we have added this concept as the third weakness/limitation of our study in the "Strenghts and Limitations" section (page 5, lines 4-6): "Important unmet needs were also identified: lack of validated criteria to diagnose bacterial acute rhinosinusitis and, in consequence, to prescribe antibiotics". Currently, we still relay in the criteria stated by EPOS 2012 (Fokkens et al, in the EPOS) where 3 or more of the 5 stated signs/symptoms (fever ≥38ºC, unilateral severe and unilateral pain, purulent rhinorrea with unilateral predominance, elevated ESR/CRP in the blood test, and double sickening) are considered to be reliable to diagnose bacterial ARS.
COMMENT 2. Although it appears to be similar in this study, is there a typical symptom (s) or question (s) that is sensitive enough to differentiate between patients with ARS and postviral ARS? ANSWER 2. We agree with the reviewer that this is an important issue to be studied. Unfortunately, in this real life study we were not able to find any difference regarding symptoms or questions between viral and postviral ARS, and the unique risk factor we found to develop postviral ARS was "working in a bad air-conditioned environment". In fact, to differentiate between viral and postviral ARS we used the EPOS criteria based on days of disease duration but not on specific symptoms (used to define rhinosinusitis) or disease severity.
COMMENT 3. Based on your exclusion criteria, did you exclude more patients with postviral ARS than ARS? ANSWER 3. This is also a very interesting question. However we are not able to answer this question since exclusion criteria was applied before recruitment and viral/postviral classification was done after recruitment. We totally agree with the reviewer it would have been scientifically interesting to study and classify excluded patients, but at that time this was not one of the study objectives.
COMMENT 4. Page 8, line, 34, home environment, what does the "Airy" meaning to? Here you have mentioned "well-heated", but in the Results, you have mentioned only "air-conditioned environment" (Page 12, line 50). ANSWER 4. We have studied outcomes such as home environment and daily activity environment. Regarding home environment we recorded patients who were living in a "well-heated home" (the temperature at home was well controlled) and patients who were living in an "airy home" (the air of the house was properly renovated and with good ventilation). Daily activity environment was referred to the work place and we recorded patients who worked in a well or poor air-conditioned environment (good or bad temperature control in the enclosure). We agree with the reviewer that using different terms to explain the same condition can induce confusion and, to unify definitions, we have changed the term "well-heated home" for "well air-conditioned home" both in the methods section (page 10, line 13) and in Table 1 (page 31).
COMMENT 5. In Fig 1, the number of percentage is confusion and need to be revised. ANSWER 5. Although the former percentages in the different boxes of Figure 1 are strictly correct, we agree with the reviewer they are difficult to understand and follow what is what, and potentially causing confusion and misunderstanding in the readers. Due to that and following the reviewer's advice, we have modified Figure 1 by removing most of the percentages while keeping the absolute number of patients in each step. However, we have kept the percentages of severity groups at Visit 1 (important to know their frequency in the whole studied population) and the percentages for the final three disease phenotypes: viral ARS (36%), postviral ARS (63%), and chronification (1%), as we think they are also important to be displayed. To clarify these different percentages, we have added letters (a and b) in superindex in the Figures, which are defined in the figure legend (page 29, lines 6-8) COMMENT 6. In Fig 1, the severity of disease is based on "VAS of pain" that is NOT same as it is mentioned in Methodology. ANSWER 6. We thank the reviewer for noticing this mistake. In Figure 1 , we have changed this expression for "VAS of disease severity", changes "slight" for "mild", and keeping the percentages of severity levels at Visit 1. In addition, we have defined the different levels of ARS severity in the methods section (page 11, lines 6-8).
REVIEWER 2 COMMENT 1. 'Viral' sinusitis for acute sinusitis. This presupposes that all acute sinusitis is viral, but this is not correct. While sinusitis episodes are frequently triggered by a respiratory virus, puncture studies suggest that significant levels of pathogens can be identified in 30-35% of appropriately diagnosed patients. These cases can and do resolve without antibiotics, hence presence of bacteria in acute sinusitis does not necessarily mean the patient requires an antibiotic treatment. However, I believe it is incorrect to term this 'viral' as opposed to the catch all 'sinusitis' term which describes simply inflammation of the sinus. ANSWER 1. We quite agree in this statement raised by the reviewer. However, in this real-life study we used the terminology, definitions, and classifications stated by the EPOS guidelines for "epidemiological studies" in ARS where "mild" disease is mainly linked to viral (common cold), moderate to postviral (inflammation), and severe to bacterial (infection) despite the presence of bacteria in sinus puncture. The EPOS document was reviewed, approved, and co-authored by a number of worldwide experts in rhinosinusitis. We realize these definitions may be not fully applicable in 100% of the cases since there are still a number of unmet needs to fully validate these classifications. On the other hand, we consider the EPOS epidemiological classifications still represent an enormous help to be used in epidemiological and real-life studies to get comparable data among different study populations.
Nevertheless, we could strongly agree in that this classification perhaps would not be totally appropriate for clinical trials or translational research studies.
COMMENT 2. Inclusion of patients from GPs. This is simple recollection of previous treatments and not prospectively collected data like that obtained from the ENTs. Given this important bias, the two are simply not comparable. ANSWER 2. We completely agree with the reviewer that data from PCPs are retrospective while from ENT specialists are prospective and tried to clarify this as a weakness of the study (page 25, line 20-23). Common cold and ARS are usually either not seen by doctors and self-treated with OTC medications, or seen mainly by PCPs. ENT specialists usually visit these patients only when they are severe or complicated. This is one of the reasons why in EPOS consensus, recommendations are different for PCPs/non-ENT specialists and ENT specialists. When designing the study, different possibilities were considered such as using both PCPs and ENTs in parallel or first by PCPs and then by ENTs when uncontrolled (in the Spanish Health System most ARS patients are being evaluated by PCPs and those uncontrolled or complicated are referred to ENT specialists). In both situations pros and cons were stated for each option. Finally, we decided the study should be performed by ENTs only but getting information from previous management by PCPs. Although a direct comparison between the ARS management by these two groups of physicians should be interpreted with caution under this study design, the resulting data was of enormous scientific interest and close to what we observe in clinical practice. Given that, the authors decided to report and compare both data sets since we were handling a very valuable information that could be used to alert general public, medical associations, and health systems about the burden of non-complicated ARS (a self-limited disease) management due to the overuse and abuse of diagnostic tools and therapeutic options. In conclusion, although there is a bias limitation data from both groups of physicians maybe be somewhat compared.
COMMENT 3. Unbalanced discussion of the usefulness of corticosteroids and management of acute sinusitis. A more complete discussion of corticosteroids for ARS would include the other published (and unpublished) trials showing weaker or no effect. This topic remains controversial. ANSWER 3. We totally agree with the reviewer the efficacy of intranasal corticosteroids in ARS is somewhat controversial but with more studies in favour than against. EPOS guidelines and data from systematic reviews and meta-analysis recommend the use of intranasal corticosteroids mainly for moderate ARS (without oral antibiotics) and severe (in combination with oral antibiotics), while recommending their use. We have tried to clarify this point in the discussion section (page 23, lines 21-25; page 24, lines 1-6).
COMMENT 4. Abuse versus overuse. The authors use the term 'according to guideline recommendations' (best practices) which I prefer to 'abuse'. It is clear that physicians do not always adhere to guidelines-however, we may not have understood how to best serve their needs either so the dialogue needs to be ongoing. ANSWER 4. We thank the reviewer for the comment and we can agree with it. Choosing the term "abuse" was mainly to emphasize and highlight the burden of using diagnostic tools and therapeutic options to mange ARS without being strictly indicated and needed which may cause high costs to patients and to National Health Systems. However, we have changed the term "abuse" by "overuse" in the title and all over the manuscript following the reviewer's suggestion (page 4, line 9; page 22, lines 13 and 19; page 26, line 21) COMMENT 5. Lack of clinical pearls for the reader on management of sub-acute sinusitis. Pearls on understanding and managing this oft-ignored entity are scattered throughout the text. A summary statement could help group these in a quick vignette e.g., " Management is similar as for ABRS and disease can be expected to resolve even when moderate or severe symptoms are present. A corticosteroid appeared to help benefit resolution" or along those lines. ANSWER 5. Although agreeing with the reviewer's suggestion we have also to adapt to the journal rules (please see Editor's Comment 6). However, we have added that summary statement at the end of the discussion section (page 25, lines 6-10) following the reviewer's suggestion: "In summary, the management of mild to moderate ARS is quite similar as for severe/bacterial ARS (apart from the need of antibiotics in specific cases) as disease can be expected to resolve even when moderate or severe symptoms are present. The use of intranasal corticosteroids appear to help benefit the resolution of disease" OTHER CHANGES:
-We have modified the STROBE check list, according the new numeration of pages, after the changes performed.
-We have changed the Figures order, so now they are cited and appear in numerical order.
-We have changed the resolution of the figures to 300dpi each. -We have attached two main documents, the first one "clean" and the second one "marked" pointing all the changes we have made.
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REVIEWER
De Yun Wang National University of Singapore, Singapore REVIEW RETURNED 20-Oct-2017
GENERAL COMMENTS
The authors have revised the paper appropriately. It is ready for publication.
